靶向抑制白细胞介素6受体对急性心梗后白细胞产生的影响  

The effect of targeting interleukin-6 receptor on leukocyte production after acute myocardial infarction

作　　者：崔春便[1] 贾新未[1] 王艳飞[1] 李雅[1] 王占启[1] 王敬[1] 

机构地区：[1]河北大学附属医院,河北保定071000

出　　处：《实用医学杂志》2018年第1期34-38,共5页The Journal of Practical Medicine

基　　金：河北医学科学研究重点课题计划资助(编号:ZL20140136)

摘　　要：目的探讨大鼠心梗后利用Tocilizumab抑制白细胞介素6(IL-6)受体对白细胞产生的影响,探讨其成为治疗心肌梗死的可能性。方法取部分大鼠做大鼠心梗模型,ELISA法、流式细胞术、血常规分别检测大鼠心梗Tocilizumab皮下注射治疗前后血IL-6、骨髓造血干细胞及血液白细胞水平,免疫组化观察大鼠心梗后心肌组织白细胞浸润及纤维化程度。结果与对照组相比,心梗发生后大鼠血液中IL-6明显升高(P<0.05),骨髓增殖期HSC的比率及血液中白细胞数量均明显增加(P<0.05)。与未治疗组相比,用IL-6R靶向抑制剂Tocilizumab治疗后骨髓增殖期HSC比率明显降低、血WBC数量减少(P<0.05),心肌重构得以改善。结论Tocilizumab可以抑制心梗后白细胞的产生并抑制心肌重构,为临床治疗MI提供了新思路。Objective To observe the effects of Tocilizumab on white blood cell （WBC） after acute myo- cardial infarction （MI） and explore its potential to treat MI. Methods Rats were divided into 3 groups： control, MI, and MI treated. Serum from individual mouse was collected before and after subcutaneously Tocilizumab treat- ment. The level of interleukin-6 （IL-6）, the number of WBC and the ratio of active hematopoietic stem cell （ HSC ） was tested by ELISA, flow cytometry and blood routine examination. The fibrosis of heart tissue was observed by im- munohistochemistry. Results The IL-6 level and the number of the WBC were reduced after Tocilizumab treat- ment. It indicates the effect of inhibiting the activity of HSC and improving the situation of cardiocytes remodeling. Conclusion Tocilizumab could inhibit the generation of WBC and re-construct myocardium after MI.

关 键 词：心肌梗死 白细胞介素 白细胞介素6受体 造血 心肌重构 

分 类 号：R542.22[医药卫生—心血管疾病]